Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506982 · ClinicalTrials.gov registry record · Phase 1
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05506982 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 11 participants.
The verdict
NCT05506982, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life.
Interventions
- OTHER Quality-of-Life Assessment
- BEHAVIORAL Psychotherapy
- OTHER Questionnaire Administration
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05506982
The ClinicalTrials.gov registry entry for NCT05506982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05506982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05506982 about?
NCT05506982 is a clinical study titled "Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain". This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, an...
What is the current status of trial NCT05506982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2022-11-01. Estimated completion is 2025-01-24.
What interventions are being tested in trial NCT05506982?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Psychotherapy (BEHAVIORAL), Questionnaire Administration (OTHER), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05506982?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.